Last reviewed · How we verify
BP31510 in combination with chemotherapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BP31510 in combination with chemotherapy (BP31510 in combination with chemotherapy) — BPGbio.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BP31510 in combination with chemotherapy TARGET | BP31510 in combination with chemotherapy | BPGbio | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BP31510 in combination with chemotherapy CI watch — RSS
- BP31510 in combination with chemotherapy CI watch — Atom
- BP31510 in combination with chemotherapy CI watch — JSON
- BP31510 in combination with chemotherapy alone — RSS
Cite this brief
Drug Landscape (2026). BP31510 in combination with chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/bp31510-in-combination-with-chemotherapy. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab